Drugs.com - Clinical Trials

First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

FOSTER CITY, Calif.--(BUSINESS WIRE) March 11, 2025 -- Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s...

Mar 11, 2025 - 21:19
 0
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
FOSTER CITY, Calif.--(BUSINESS WIRE) March 11, 2025 -- Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s...
Read More

Tags:

Previous Article

EXCLUSIVE: Social Wellness Club Remedy Place Is Headed to Boston With a Foam Bat...

Next Article

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody...

Related Posts

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of Duravyu for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

EyePoint Announces Positive Six-Month Results for the P...

Feb 9, 2025  0

Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Merck Announces Phase 3 waveLINE-010 Trial Initiation E...

Feb 9, 2025  0

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Innate Pharma Announces U.S. FDA Granted Breakthrough T...

Feb 17, 2025  0